Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07182526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 19, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study will investigate whether the addition of Quercetin or Alpha-Lipoic Acid (ALA) to standard metformin therapy can improve symptoms, hormone levels, metabolic health, and quality of life in women with polycystic ovary syndrome (PCOS). Over 3 months, participants will be randomly assigned to one of three groups: metformin alone, metformin plus Quercetin, or metformin plus ALA. Researchers will measure changes in hormones, blood sugar, cholesterol, and antioxidant markers, as well as quality of life and medication adherence. Physical measurements and side effects will also be recorded to assess safety and overall benefit.
Trial Details
NCT Number NCT07182526
Lead Sponsor Al-Mustansiriyah University
Conditions
(from sponsor)		 PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Related terms Polycystic Ovary Syndrome
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov